Register for email alerts and news feeds:
This journal | BMJ Group
rss
British Journal of Ophthalmology 2004;88:336-340; doi:10.1136/bjo.2003.021907
Copyright © 2004 by the BMJ Publishing Group Ltd.
British Journal of Ophthalmology 2004;88:336-340
© 2004 BMJ Publishing Group Ltd

SCIENTIFIC REPORT

Randomised double masked trial comparing the efficacy and tolerance of 0.05% mequitazine eye drops versus 0.05% levocabastine and placebo in allergic conjunctivitis induced by a conjunctival provocation test with Dermatophagoides pteronyssinus

B Mortemousque1, A Jacquet2, C Richard3, F Depont2, J Colin1 and N Moore2

1 Service d’Ophtalmologie, CHU de Bordeaux, 33076 Bordeaux, France
2 Département de Pharmacologie, CHU de Bordeaux, France
3 Laboratoire Chauvin Bausch & Lomb, Montpellier, France

Correspondence to:
Correspondence to:
Bruno Mortemousque MD, PhD
Service d’Ophtalmologie, CHU de Bordeaux, 33076 Bordeaux, France; bruno.mortemousque{at}chu-bordeaux.fr

ABSTRACT

Aim: A double masked randomised trial comparing 0.05% mequitazine eye drops with 0.05% levocabastine and placebo was carried out in otherwise heatlhy volunteers allergic to house dust mites (Dermatophagoides pteronyssinus).

Method: Double masked, randomised, single centre study, comparing three parallel treatment groups. 60 healthy adults with a confirmed history of allergic conjunctivitis to house dust mites for at least 2 years were included and completed the trial. Conjunctival provocation tests (CPT) were done at screening, at visit 2 (V2) (1 week later), and at visit 3 (V3) (2 weeks after V2). Treatment was instilled in the same eye, 5 minutes after the CPT at V2, and twice daily until V3. CPT were scored 5, 10, 15, and 60 minutes after instillation of the dose of Dermatophagoides pteronyssinus antigen determined at inclusion (V2, curative test) or resulting in positivity (V3, preventive test)

Results: In the V2 (curative) test the difference between the active treatments and placebo on the redness+itching scores was not significant. At the V3 (preventive) CPT there was a lower number of reactions at the threshold dose with mequitazine (20%) compared to placebo (60%, p = 0.01) or levocabastine (45%, p = 0.10).

Conclusion: This trial failed to clearly demonstrate curative superiority of topical antihistamines with placebo, when a single dose of treatment was instilled following CPT. However mequitazine 0.05% eye drops were superior to placebo in preventing a reaction to CPT, after 2 weeks of treatment.

Keywords: mequitazine; conjunctival provocation test


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Ophthalmology Jobs

Ophthalmology Jobs